BeiGene Ltd stock (US07725L1026): Brukinsa tops $2.5 billion annual run-rate as US oncology footprint expands

BeiGene Ltd reported that BTK inhibitor Brukinsa has surpassed a $2.5 billion annual commercial revenue run?rate on its Q1 2026 figures, underscoring the company’s growing presence in the US oncology market and raising investor focus on its broader cancer drug portfolio.

BeiGene Ltd has highlighted a major commercial milestone for its BTK inhibitor Brukinsa, which crossed an annualized commercial revenue run-rate of roughly $2.5 billion based on first-quarter 2026 results disclosed in May, signaling strong momentum in the US hematology-oncology market according to The Platinum Capital as of 05/20/2026.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: BeiGene
• Sector/industry: Biotechnology, oncology
• Headquarters/country: Beijing, China
• Core markets: United States, China, global oncology
• Key revenue drivers: Brukinsa (zanubrutinib) and partnered oncology products
• Home exchange/listing venue: Nasdaq (BGNE); Hong Kong; Shanghai STAR Market
• Trading currency: Primarily USD on Nasdaq, HKD in Hong Kong, CNY on STAR Market

BeiGene Ltd: core business model

BeiGene Ltd is a global oncology-focused biotechnology company that discovers, develops and commercializes treatments for cancer patients worldwide, with a strategy built around both internally discovered drugs and partnered assets, according to the company’s corporate profile on its website BeiGene website as of 05/21/2026.

The company’s model combines large-scale research operations in China with commercial infrastructures in North America, Europe and other regions, aiming to deliver targeted therapies and immuno-oncology medicines across hematologic malignancies and solid tumors, as described in its investor materials on BeiGene investor relations as of 03/27/2024.

BeiGene generates revenue from sales of its own branded medicines, milestone and royalty income from partners, and, in some markets, co-promotion arrangements, providing a diversified but oncology-centric income base that is increasingly tied to growth in the US and other developed healthcare systems.

Main revenue and product drivers for BeiGene Ltd

Brukinsa, a Bruton’s tyrosine kinase inhibitor used in certain B?cell malignancies, has become the centerpiece of BeiGene’s commercial portfolio, with the product’s annualized revenue run-rate surpassing $2.5 billion based on Q1 2026 commercial sales disclosed in May, according to The Platinum Capital as of 05/20/2026.

The company also markets tislelizumab, an anti?PD?1 antibody commercialized in China and, via partnerships, in other regions, as well as additional oncology therapies either self-developed or in-licensed, with management positioning these assets as complementary to Brukinsa in core hematology and immuno-oncology segments as noted in earlier earnings commentary on BeiGene investor relations as of 02/28/2024.

For US investors, the growth trajectory of Brukinsa in the American market is particularly important because the US remains the largest global payer for oncology drugs, and incremental share gains against established BTK inhibitors can have an outsized impact on BeiGene’s consolidated revenue and margin profile over time.

Conclusion

BeiGene Ltd has underlined its status as a rising global oncology player with Brukinsa now exceeding a $2.5 billion annual revenue run-rate on Q1 2026 figures, supported by an expanding US footprint and a broader pipeline of cancer medicines, while investors continue to monitor competitive dynamics in BTK inhibition and regulatory developments in key markets.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.